SK bioscience : Material Business Matters Related to Investment Decisions (Approval of the domestic product licensing for COVID-19 vaccine SKYCovione(GBP510))

Material Business Matters Related to Investment Decisions

1. Title	Approval of the domestic product licensing for COVID-19 vaccine SKYCovione(GBP510)
2. Details	1) Product name - SKYCovione(GBP510) 2) Target disease (indications) - Prevention of COVID-19 infection caused by SARS-CoV-2 3) Date of application for product approval, Date of approval and approval agency - Date of application: 2022-04-29 - Date of approval: 2022-06-29 - Product licensing agency: Ministry of Food and Drug Safety (MFDS) 4) Expected effect: -SKYCovione is a recombinant protein nanoparticle vaccine containing the receptor binding domain of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03). - Strong neutralizing antibodies that may contribute to the prevention of COVID-19 were induced by primary vaccination of SKYCovione. In terms of safety, overall, SKYCovione showed a clinically acceptable safety profile. - SKYCovione is a thermostable refrigerated vaccine which could be an interesting feature in various countries. - In addition, booster dose neutralizing antibody response is currently being evaluated in clinical trials. 5) Future plan: - Domestic and foreign supply with global license application planned
3. Date of board resolution (decision date) or confirmation date	2022-06-29
- Attendance of outside directors	Present(No.)	-
Absent(No.)	-
- Attendance of auditors (members of Audit Committee who are not outside directors)	-
4. Other matters to be factored into investment decisions
- The above '3. Date of board resolution (decision date) or confirmation date' is the date of the approval.
※ Related disclosure	2022-05-02 Material Business Matters Related to Investment Decisions(Application for the domestic product licensing for COVID-19 vaccine GBP510) 2022-05-02 Material Business Matters Related to Investment Decisions(Announcement of the key results of Phase III clinical of COVID-19 vaccine GBP510)